Status:
COMPLETED
IDA (Immunothérapie de la Dermatite Atopique) Adult - Immunotherapy in Atopic Dermatitis
Lead Sponsor:
Institut National de la Santé Et de la Recherche Médicale, France
Collaborating Sponsors:
Ministry of Health, France
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Atopic dermatitis (AD) is a chronic inflammatory disease of the skin. AD is very frequent, and involves T lymphocytes cells. Measles vaccination, as well as measles vaccine, induces a temporary immuno...
Detailed Description
Atopic dermatitis (AD) is a chronic inflammatory disease of the skin. AD is very frequent, and involves T lymphocytes cells. Measles vaccination, as well as measles vaccine, induces a temporary immuno...
Eligibility Criteria
Inclusion
- adults patients of both sexes, with moderate to severe Atopic Dermatitis (SCORAD (Score for Atopic Dermatitis) ≥ 15).
Exclusion
- hypersensititvity or contra-indication to a Rouvax® component, Tubertest® component, to egg proteins, immunological deficiency, pregnancy, neomycin
- allergy,
- systemic immnosuppressive treatment in the previous 3 months,
- topic immunosuppressive treatment during the week preceeding the inclusion (gluco-corticoid, or immunosuppressive agent),
- fever or acute disease (the inclusion must be postpone in such cases).
Key Trial Info
Start Date :
January 9 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 26 2012
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00820820
Start Date
January 9 2009
End Date
March 26 2012
Last Update
February 12 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Unité de Recherche Clinique et Immunologique
Pierre-Bénite, Lyon, France, 69495